Volume 16, issue 1, December 2023
123 articles in this issue
-
-
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
Authors (first, second and last of 45)
-
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities
Authors (first, second and last of 7)
-
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types
Authors (first, second and last of 8)
-
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2
Authors (first, second and last of 28)
This is part of 2 collections:
-
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
Authors (first, second and last of 11)
-
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
Authors (first, second and last of 26)
-
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy
Authors (first, second and last of 6)
-
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
Authors (first, second and last of 13)
-
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment
Authors (first, second and last of 7)
-
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
Authors (first, second and last of 11)
-
Genitourinary cancers updates: highlights from ASCO 2023
Authors (first, second and last of 5)
This is part of 2 collections: -
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
Authors (first, second and last of 29)
-
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma
Authors (first, second and last of 20)
-
Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA
Authors (first, second and last of 13)
-
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Authors (first, second and last of 5)
-
-
-
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Authors (first, second and last of 5)
-
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Authors (first, second and last of 19)
-
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Authors (first, second and last of 7)
-
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
Authors (first, second and last of 10)
-
-
Recent advances in targeted strategies for triple-negative breast cancer
Authors (first, second and last of 7)
-
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Authors (first, second and last of 7)
-
Advances in single-cell RNA sequencing and its applications in cancer research
Authors (first, second and last of 12)
-
-
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Authors (first, second and last of 18)
This is part of 2 collections:
-
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
Authors (first, second and last of 14)
-
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Authors (first, second and last of 14)
-
-
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Authors (first, second and last of 5)
This is part of 2 collections: -
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
Authors (first, second and last of 19)
-
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Authors (first, second and last of 4)
This is part of 2 collections: -
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
Authors (first, second and last of 5)
-
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Authors (first, second and last of 18)
-
-
-
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
Authors (first, second and last of 11)
This is part of 2 collections: -
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis
Authors (first, second and last of 15)
-
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Authors (first, second and last of 5)
-
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Authors (first, second and last of 17)
-
-
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Authors (first, second and last of 37)
-
Novel target and treatment agents for natural killer/T-cell lymphoma
Authors (first, second and last of 10)
-
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Authors (first, second and last of 10)
-
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
Authors (first, second and last of 17)
-
-
